Oral nicotine in treatment of primary sclerosing cholangitis. A pilot study

Paul Angulo, Adil Eddie Bharucha, Roberta A. Jorgensen, Carolee K. DeSotel, William J. Sandborn, Nicholas F La Russo, Keith D. Lindor

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Currently, no accepted medical therapy for patients with primary sclerosing cholangitis (PSC) is available. Case-control studies have shown an inverse association between PSC and smoking behavior, suggesting that nicotine might have a beneficial effect in PSC. The aim of this study was to evaluate the safety and estimate the efficacy of oral nicotine in the treatment of PSC. Eight PSC patients who had never smoked received oral nicotine at a maximum dose of 6 mg four times a day for up to one year. Liver biochemistries and plasma cotinine levels were determined at entry and at three-month intervals during the study duration. Five patients completed one year of treatment, but three of them had to temporarily reduce the dose due to side effects. One patient completed only four months of treatment due to dizziness and heart palpitations. Two patients completed only one month of treatment due to reactivation of colitis requiring corticosteroid therapy. No significant changes in liver biochemistries were noted during the treatment period despite a significant increase in plasma cotinine levels. In conclusion, oral nicotine seems to have no beneficial effects in the treatment of PSC, and it is frequently associated with side effects necessitating permanent drug cessation.

Original languageEnglish (US)
Pages (from-to)602-607
Number of pages6
JournalDigestive Diseases and Sciences
Volume44
Issue number3
StatePublished - 1999

Fingerprint

Sclerosing Cholangitis
Nicotine
Cotinine
Therapeutics
Biochemistry
Liver
Dizziness
Colitis
Case-Control Studies
Adrenal Cortex Hormones
Smoking
Safety

Keywords

  • Inflammatory bowel disease
  • Oral nicotine
  • Primary sclerosing cholangitis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Angulo, P., Bharucha, A. E., Jorgensen, R. A., DeSotel, C. K., Sandborn, W. J., La Russo, N. F., & Lindor, K. D. (1999). Oral nicotine in treatment of primary sclerosing cholangitis. A pilot study. Digestive Diseases and Sciences, 44(3), 602-607.

Oral nicotine in treatment of primary sclerosing cholangitis. A pilot study. / Angulo, Paul; Bharucha, Adil Eddie; Jorgensen, Roberta A.; DeSotel, Carolee K.; Sandborn, William J.; La Russo, Nicholas F; Lindor, Keith D.

In: Digestive Diseases and Sciences, Vol. 44, No. 3, 1999, p. 602-607.

Research output: Contribution to journalArticle

Angulo, P, Bharucha, AE, Jorgensen, RA, DeSotel, CK, Sandborn, WJ, La Russo, NF & Lindor, KD 1999, 'Oral nicotine in treatment of primary sclerosing cholangitis. A pilot study', Digestive Diseases and Sciences, vol. 44, no. 3, pp. 602-607.
Angulo, Paul ; Bharucha, Adil Eddie ; Jorgensen, Roberta A. ; DeSotel, Carolee K. ; Sandborn, William J. ; La Russo, Nicholas F ; Lindor, Keith D. / Oral nicotine in treatment of primary sclerosing cholangitis. A pilot study. In: Digestive Diseases and Sciences. 1999 ; Vol. 44, No. 3. pp. 602-607.
@article{10ebbb5879424737983e4cbbe320ee3f,
title = "Oral nicotine in treatment of primary sclerosing cholangitis. A pilot study",
abstract = "Currently, no accepted medical therapy for patients with primary sclerosing cholangitis (PSC) is available. Case-control studies have shown an inverse association between PSC and smoking behavior, suggesting that nicotine might have a beneficial effect in PSC. The aim of this study was to evaluate the safety and estimate the efficacy of oral nicotine in the treatment of PSC. Eight PSC patients who had never smoked received oral nicotine at a maximum dose of 6 mg four times a day for up to one year. Liver biochemistries and plasma cotinine levels were determined at entry and at three-month intervals during the study duration. Five patients completed one year of treatment, but three of them had to temporarily reduce the dose due to side effects. One patient completed only four months of treatment due to dizziness and heart palpitations. Two patients completed only one month of treatment due to reactivation of colitis requiring corticosteroid therapy. No significant changes in liver biochemistries were noted during the treatment period despite a significant increase in plasma cotinine levels. In conclusion, oral nicotine seems to have no beneficial effects in the treatment of PSC, and it is frequently associated with side effects necessitating permanent drug cessation.",
keywords = "Inflammatory bowel disease, Oral nicotine, Primary sclerosing cholangitis, Ulcerative colitis",
author = "Paul Angulo and Bharucha, {Adil Eddie} and Jorgensen, {Roberta A.} and DeSotel, {Carolee K.} and Sandborn, {William J.} and {La Russo}, {Nicholas F} and Lindor, {Keith D.}",
year = "1999",
language = "English (US)",
volume = "44",
pages = "602--607",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Oral nicotine in treatment of primary sclerosing cholangitis. A pilot study

AU - Angulo, Paul

AU - Bharucha, Adil Eddie

AU - Jorgensen, Roberta A.

AU - DeSotel, Carolee K.

AU - Sandborn, William J.

AU - La Russo, Nicholas F

AU - Lindor, Keith D.

PY - 1999

Y1 - 1999

N2 - Currently, no accepted medical therapy for patients with primary sclerosing cholangitis (PSC) is available. Case-control studies have shown an inverse association between PSC and smoking behavior, suggesting that nicotine might have a beneficial effect in PSC. The aim of this study was to evaluate the safety and estimate the efficacy of oral nicotine in the treatment of PSC. Eight PSC patients who had never smoked received oral nicotine at a maximum dose of 6 mg four times a day for up to one year. Liver biochemistries and plasma cotinine levels were determined at entry and at three-month intervals during the study duration. Five patients completed one year of treatment, but three of them had to temporarily reduce the dose due to side effects. One patient completed only four months of treatment due to dizziness and heart palpitations. Two patients completed only one month of treatment due to reactivation of colitis requiring corticosteroid therapy. No significant changes in liver biochemistries were noted during the treatment period despite a significant increase in plasma cotinine levels. In conclusion, oral nicotine seems to have no beneficial effects in the treatment of PSC, and it is frequently associated with side effects necessitating permanent drug cessation.

AB - Currently, no accepted medical therapy for patients with primary sclerosing cholangitis (PSC) is available. Case-control studies have shown an inverse association between PSC and smoking behavior, suggesting that nicotine might have a beneficial effect in PSC. The aim of this study was to evaluate the safety and estimate the efficacy of oral nicotine in the treatment of PSC. Eight PSC patients who had never smoked received oral nicotine at a maximum dose of 6 mg four times a day for up to one year. Liver biochemistries and plasma cotinine levels were determined at entry and at three-month intervals during the study duration. Five patients completed one year of treatment, but three of them had to temporarily reduce the dose due to side effects. One patient completed only four months of treatment due to dizziness and heart palpitations. Two patients completed only one month of treatment due to reactivation of colitis requiring corticosteroid therapy. No significant changes in liver biochemistries were noted during the treatment period despite a significant increase in plasma cotinine levels. In conclusion, oral nicotine seems to have no beneficial effects in the treatment of PSC, and it is frequently associated with side effects necessitating permanent drug cessation.

KW - Inflammatory bowel disease

KW - Oral nicotine

KW - Primary sclerosing cholangitis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0033029441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033029441&partnerID=8YFLogxK

M3 - Article

C2 - 10080157

AN - SCOPUS:0033029441

VL - 44

SP - 602

EP - 607

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -